AGTR1 and hydrops fetalis: Certainly, the data in Foster et al. challenge us to consider the potential application of BBB permeant pharmacological interventions, especially early in the HF disease process, to inhibit AT1 receptor- and βAR-stimulated ventilatory overdrive and mitigate diaphragmatic myopathy.